Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

Ozempic is technically a diabetes medication, but its maker Novo Nordisk markets a related product called Wegovy for weight ...

Henrik Wulff, the man in charge of product supply at Novo Nordisk, just spent $11 billion to try to fill an ocean. Novo has ...

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes ...

El Salvador will sell or discontinue wallet Chivo as part of deal. GDP revised higher. Micron stumbles and quantum computing ...

Danish pharmaceutical company Novo Nordisk recently announced plans to spend approximately $1.2 billion to build a new ...

Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non ...

But once the shortage is over, patent enforcements go back into full swing. Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for ...

But, with the outsized demand for Mounjaro and Zepbound and Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy, it has become a ...